85 related articles for article (PubMed ID: 14727896)
1. Novel mathematical method for quantitative expression of deviation from the higuchi model.
Gohel MC; Panchal MK; Jogani VV
AAPS PharmSciTech; 2000 Oct; 1(4):E31. PubMed ID: 14727896
[TBL] [Abstract][Full Text] [Related]
2. In-vitro studies of diclofenac sodium controlled-release from biopolymeric hydrophilic matrices.
Bravo SA; Lamas MC; Salamón CJ
J Pharm Pharm Sci; 2002; 5(3):213-9. PubMed ID: 12553888
[TBL] [Abstract][Full Text] [Related]
3. [The use of natural and synthetic hydrophilic polymers in the formulation of metformin hydrochloride tablets with different profile release].
Kołodziejczyk MK; Kołodziejska J; Zgoda MM
Polim Med; 2012; 42(3-4):167-84. PubMed ID: 23457958
[TBL] [Abstract][Full Text] [Related]
4. Formulation development and in vitro evaluation of theophylline microcapsules.
Ahmad M; Akhtar N; Murtaza G; Hussain SW
Pak J Pharm Sci; 2012 Jan; 25(1):15-9. PubMed ID: 22186304
[TBL] [Abstract][Full Text] [Related]
5. [Technological and pharmacotherapeutic properties of selected drugs with modified release of diclofenac sodium].
Kołodziejczyk MK; Kołodziejska J; Zgoda MM
Polim Med; 2012; 42(2):121-32. PubMed ID: 23016443
[TBL] [Abstract][Full Text] [Related]
6. Testing lyoequivalency for three commercially sustained-release tablets containing diltiazem hydrochloride.
Maswadeh HA; Al-Hanbali OA; Kanaan RA; Shakya AK; Maraqa A
Acta Pol Pharm; 2010; 67(1):93-7. PubMed ID: 20210085
[TBL] [Abstract][Full Text] [Related]
7. Preparation and in vitro evaluation of sustained release tablet formulations of diclofenac sodium.
Savaşer A; Ozkan Y; Işimer A
Farmaco; 2005 Feb; 60(2):171-7. PubMed ID: 15752476
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceutical Product Lead Optimization for Better In vivo Bioequivalence Performance: A case study of Diclofenac Sodium Extended Release Matrix Tablets.
Shahiwala A; Zarar A
Curr Drug Deliv; 2018; 15(5):705-715. PubMed ID: 29165078
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of drug release kinetics from ibuprofen matrix tablets using HPMC.
Shoaib MH; Tazeen J; Merchant HA; Yousuf RI
Pak J Pharm Sci; 2006 Apr; 19(2):119-24. PubMed ID: 16751122
[TBL] [Abstract][Full Text] [Related]
10. Preparation and in-vitro in-vivo evaluation of sustained release matrix diclofenac sodium tablets using PVP-K90 and natural gums.
Iqbal Z; Khan R; Nasir F; Khan JA; Rashid A; Khan A; Khan A
Pak J Pharm Sci; 2011 Oct; 24(4):435-43. PubMed ID: 21959802
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
[TBL] [Abstract][Full Text] [Related]
12. Report: in vitro dissolution studies of different brands of sustained release diclofenac sodium matrix tablet available in Bangladesh.
Abdullah MD; Bepary S; Rouf AS
Pak J Pharm Sci; 2008 Jan; 21(1):70-7. PubMed ID: 18166523
[TBL] [Abstract][Full Text] [Related]
13. Design, development and in-vitro evaluation of metoprolol tartrate tablets containing xanthan-tragacanth.
Rasul A; Iqbal M; Murtaza G; Waqas MK; Hanif M; Khan SA; Bhatti NS
Acta Pol Pharm; 2010; 67(5):517-22. PubMed ID: 20873420
[TBL] [Abstract][Full Text] [Related]
14. Formulation and evaluation of natural gum-based sustained release matrix tablets of flurbiprofen using response surface methodology.
Shah SN; Asghar S; Choudhry MA; Akash MS; ur Rehman N; Baksh S
Drug Dev Ind Pharm; 2009 Dec; 35(12):1470-8. PubMed ID: 19929206
[TBL] [Abstract][Full Text] [Related]
15. Formulation and evaluation of mucoadhesive matrix tablets of taro gum: optimization using response surface methodology.
Arora G; Malik K; Singh I
Polim Med; 2011; 41(2):23-34. PubMed ID: 21866794
[TBL] [Abstract][Full Text] [Related]
16. Graft copolymers of ethyl methacrylate on waxy maize starch derivatives as novel excipients for matrix tablets: drug release and fronts movement kinetics.
Marinich JA; Ferrero C; Jiménez-Castellanos MR
Eur J Pharm Biopharm; 2012 Apr; 80(3):674-81. PubMed ID: 22210473
[TBL] [Abstract][Full Text] [Related]
17. [Formulation optimization and drug release in vitro of membrane controlled tablets of puerarin inclusion compound].
Zhang E; Tan R; Gu J; He LL; Yao F
Zhongguo Zhong Yao Za Zhi; 2013 Jan; 38(1):49-52. PubMed ID: 23596875
[TBL] [Abstract][Full Text] [Related]
18. Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine.
Tanaka N; Imai K; Okimoto K; Ueda S; Tokunaga Y; Ohike A; Ibuki R; Higaki K; Kimura T
J Control Release; 2005 Nov; 108(2-3):386-95. PubMed ID: 16253377
[TBL] [Abstract][Full Text] [Related]
19. Optimization of matrix tablets controlled drug release using Elman dynamic neural networks and decision trees.
Petrović J; Ibrić S; Betz G; Đurić Z
Int J Pharm; 2012 May; 428(1-2):57-67. PubMed ID: 22402474
[TBL] [Abstract][Full Text] [Related]
20. Two different approaches for the prediction of in vivo plasma concentration-time profile from in vitro release data of once daily formulations of diltiazem hydrochloride.
Bendas ER
Arch Pharm Res; 2009 Sep; 32(9):1317-29. PubMed ID: 19784589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
